Xolair indicated for hives

Share this article:

Genentech's asthma medication Xolair is now indicated for allergic asthma and chronic idiopathic urticaria, aka chronic hives.

The drugmaker announced Monday that the FDA approved the expanded indication, which makes it the first biologic medicine approved for chronic hives.

The approval is limited to patients 12 and older who do not respond to H1 antihistamine therapy. Genentech estimates that about 50% of patients have “an inadequate response” to H1 antihistamine treatment.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.